2014


To access this material please log in or register

Register Authorize
2014/№5

Effect of cardiac resynchronization therapy on neuro-humoral activity and processes of systemic inflammation in patients with chronic heart failure

Kuznetsov V. A., Soldatova A. M.
Tyumen Cardiology Center, Melnikaite 111, Tyumen, 625026

Keywords: neuro-humoral status, prognosis, resynchronization therapy, systemic inflammation, CHF


DOI: 10.18087 / rhfj.2014.5.2003

The concept of neuro-humoral activation and systemic inflammation underlies the current theory of CHF pathogenesis. At present, cardiac resynchronization therapy (CRT) remains a standard for treatment of patients with severe CHF. This review focused on the effect of CRT on levels of natriuretic peptides and inflammation mediators.
  1. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  2. Руденко Т. Е., Кутырина И. М., Васильева М. П. Натрий­уре­ти­чес­кие пеп­тиды: диагностическое и прогностическое значения при хронической болезни почек. Клиническая нефрология. 2013;2:5–9.
  3. Chopra S, Cherian D, Verghese PP, Jacob JJ. Physiology and clinical significance of natriuretic hormones. Indian J Endocrinol Metab. 2013 Jan;17 (1):83–90.
  4. Елисеев О. М. Натрийуретические пептиды. Эволюция знаний. Терапевтический архив. 2003;75 (9):40–45.
  5. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33 (14):1787–847.
  6. Savarese G, Trimarco B, Dellegrottaglie S et al.Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One. 2013 Mar 5;8 (3):e58287.
  7. Brignole M, Auricchio A, Baron-Esquivias G et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013 Aug;34 (29):2281–329.
  8. Raab S, Oertel F, Weimann T et al. Brain natriuretic peptide – a reliable parameter for the effectiveness of cardiac resynchronization therapy after coronary artery bypass grafting. Interact Cardiovasc Thorac Surg. 2006 Aug;5 (4):439–43.
  9. Kuznetsov VA, Soldatova AM, Enina TN et al. Dynamics of natriuretic peptide and inflammatory markers in patients with implanted devices for cardiac resynchronisation therapy. Eur J Heart Fail Suppl. 2014;16 (Suppl. 2):P 857.
  10. Piepoli MF, Villani GQ, Corrà U et al. Time course of effects of cardiac resynchronization therapy in chronic heart failure: benefits in patients with preserved exercise capacity. PACE. 2008 Jun;31 (6):701–8.
  11. Brenyo A, Barsheshet A, Rao M et al. Brain natriuretic peptide and cardiac resynchronization therapy in atients with mildly sympto­matic heart failure. Circ Heart Failure. 2013 Sep;6 (5):998–1004.
  12. Wiliński J, Czarnecka D, Wojciechowska W et al. Baseline tissue Doppler imaging-derived echocardiographic parameters and left ventricle reverse remodelling following cardiac resynchronization therapy introduction. Arch Med Sci. 2011;7 (5):813–22.
  13. Yu CM, Fung JW, Zhang Q et al. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure. Journal of cardiac failure. 2005 Jun;11 (5 Suppl): S42–46.
  14. Dichtl W, Strohmer B, Fruhwald F. Clinical outcome after 1 year of cardiac resynchronisation therapy: national results from the European CRT survey. Wien Klin Wochenschr. 2013 Dec;125 (23-24):750–4.
  15. Erol-Yilmaz A, Verberne HJ, Schrama TA et al. Cardiac resynchronization induces favorable neurohumoral changes. PACE. 2005 Apr;28 (4):304–10.
  16. Berger R, Shankar A, Fruhwald F et al. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. Eur Heart J. 2009 Sep;30 (17):2109–16.
  17. Braun MU, Rauwolf T, Zerm T et al. Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones. Heart. 2005 May;91 (5):601–5.
  18. Tarquini R, Guerra CT, Porciani MC et al. Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure. Cardiol J. 2009;16 (6): 545–52.
  19. Dong YХ, Burnett Jr JC, Chen HH et al. Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure. J Interv Card Electrophysiol. 2011 Apr;30 (3):241–9.
  20. Kuznetsov VA, Soldatova AM, Enina TN et al. Dynamics of natriuretic peptide and inflammatory markers in patients with implanted devices for cardiac resynchronisation therapy. Eur J Heart Fail Suppl. 2014;16 (Suppl. 2):P 242.
  21. Ding LG, Hua W, Zhang S et al. Decrease of plasma N-terminal pro В-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure. Chinese Med J. 2009 Mar 20;122 (6):617–21.
  22. Brouwers C, Versteeg H, Meine M et al. Association between brain natriuretic peptide, markers of inflammation and the objective and subjective response to cardiac resynchronization therapy. Brain Behav Immun. 2014 Aug;40:211–8.
  23. Magne J, Dubois M, Champagne J et al. Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy. Cardiovasc Ultrasound. 2009 Aug 20;7:39.
  24. Lellouche N, De Diego C, Cesario DA et al. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. Am J Cardiol. 2007 Jan 15;99 (2):242–6.
  25. Hoogslag GE, Höke U, Thijssen J et al. Clinical, echocardiographic, and neurohormonal response to cardiac resynchronization therapy: are they interchangeable? PACE. 2013 Nov;36 (11):1391–401.
  26. Yu CM, Sanderson JE, Gorcsan J. Echocardiography, dyssynchrony, and the response to cardiac resynchronization therapy. Eur Heart J. 2010 Oct;31 (19):2326–37.
  27. Dokainish H, Zoghbi WA, Ambriz E et al. Comparative cost-effectiveness of B-type natriuretic peptide and echocardiography for predicting outcome in patients with congestive heart failure. Am J Cardiol. 2006 Feb 1;97 (3):400–3.
  28. Харченко Е. П. Сердечная недостаточность: патогенетический континуум и биомаркеры. Кардиология. 2012;52 (3):53–64.
  29. Hofmann U, Frantz S. How can we cure a heart «in flame»? A translational view on inflammation in heart failure. Basic Res Cardiol. 2013 Jul;108 (4):356.
  30. Gullestad L, Ueland T, Vinge LE et al. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012 Jun;122 (1):23–35.
  31. Oikonomou E, Tousoulis D, Siasos G et al. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol. 2011 Jan;52 (1):30–40.
  32. Voors AA, Dorhout B, Van der Meer P. The potential role of valsartan+ AHU377 (LCZ696) in the treatment of heart failure. Exp Opin Invest Drugs. 2013 Aug;22 (8):1041–7.
  33. Егорова Е. Н., Калинкин М. Н., Мазур Е. С. Иммунные механизмы в патогенезе хронической сердечной недостаточности. Патологическая физиология и экспериментальная терапия. 2012;2:56–61.
  34. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP et al. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monitor. 2009 Dec;15 (12):ms12–23.
  35. Stanciu AE, Vatasescu RG, Stanciu MM et al. Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects. Clin Biochem. 2013 Feb;46 (3):230–4.
  36. Lappegård KT, Bjørnstad H. Anti‐Inflammatory Effect of Cardiac Resynchronization Therapy. PACE. 2006 Jul;29 (7):753–8.
  37. Przybyła A, Czarnecka D, Kusiak A et al. The influence of cardiac resynchronization therapy on selected inflammatory markers and aldosterone levels in patients with chronic heart failure. Przegl Lek. 2011;68 (7):359–61.
  38. Orrego CM, Nasir N, Oliveira GH et al. Cellular evidence of reverse cardiac remodeling induced by cardiac resynchronization therapy. Congest Heart Fail. 2011 May-Jun;17 (3):140–6.
  39. Boriani G, RegolI F, Saporito D et al. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. Peptides. 2006 Jul;27 (7):1776–86.
  40. Seifert M, Schlegl M, Hoersch W et al. Functional capacity and changes in the neurohormonal and cytokine status after long-term CRT in heart failure patients. Int J Cardiol. 2007 Sep 14;121 (1):68–73.
  41. Menardi E, Vado A, Rossetti G et al. Cardiac resynchronization therapy modifies the neurohormonal profile, hemodynamic and functional capacity in heart failure patients. Arch Med Res. 2008 Oct;39 (7):702–8.
  42. Osmancik P, Herman D, Stros P et al. Changes and prognostic impact of apoptotic and inflammatory cytokines in patients treated with cardiac resynchronization therapy. Cardiology. 2013 Mar;124 (3):190–8.
  43. Shinohara T, Takahashi N, Saito S et al. Effect of cardiac resynchronization therapy on cardiac sympathetic nervous dysfunction and serum C-reactive protein level. PACE. 2011 Oct;34 (10):1225–30.
  44. Theodorakis GN, Flevari P, Kroupis C et al. Antiinflammatory effects of cardiac resynchronization therapy in patients with chronic heart failure. Pacing Clin Electrophysiol. 2006 Mar;29 (3):255–61.
  45. Rubaj A, Ruciński P, Oleszczak K et al. Inflammatory activation following interruption of long-term cardiac resynchronization therapy. Heart Vessels. 2013 Sep;28 (5):583–8.
  46. Satoh M, Minami Y, Takahashi Y, Nakamura M. Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. Curr Heart Fail Rep. 2008 Jun;5 (2):69–74.
  47. Kuznetsov V, Pokushalov E, Chudinov G et al. Indications for cardiac resynchronisation therapy in heart failure patients: from guidelines to practice in the PANORAMA-RUSSIA observational study. Available at http://circ.ahajournals.org / content / 122 / 2 / e16.full.pdf.
Kuznetsov V. A., Soldatova A. M. Effect of cardiac resynchronization therapy on neuro-humoral activity and processes of systemic inflammation in patients with chronic heart failure. Russian Heart Failure Journal. 2014;15 (5): 301–304

To access this material please log in or register

Register Authorize
Ru En